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Abstract 
Background: It remains unclear what the antiviral therapy affects disease‑free survival (DFS) and overall survival (OS) 
of patients with hepatitis B virus (HBV)‑related hepatocellular carcinoma (HCC) at different tumor stages and baseline 
HBV DNA levels. In this study, we analyzed the association of antiviral treatment with DFS and OS based on the stratifi‑
cation of baseline HBV DNA load in early‑stage (stages I and II) HCC patients.
Methods: We included 445 patients with early‑stage HBV‑related HCC who underwent curative resection, and then 
classified them into four subgroups based on baseline HBV DNA load and antiviral therapy stratification. The Kaplan–
Meier and Cox regression analyses were performed to determine the association of clinical characteristics with 
survival.
Results: The median follow‑up period was 74 months. For all patients, cumulative OS rates in the antiviral group were 
significantly higher than those in the non‑antiviral group (log‑rank test, P = 0.023), whereas no significant differences 
in DFS rates were observed. High baseline HBV DNA level was a risk factor associated with short DFS and OS in all 
patients. In patients with baseline HBV DNA levels ≥2000 IU/mL, antiviral treatment was significantly associated with 
prolonged DFS and OS (log‑rank test, P = 0.041 and 0.001, respectively). In patients with HBV DNA levels <2000 IU/mL 
or undetectable, antiviral treatment did not show a significant benefit in prolonging DFS and OS.
Conclusions: High baseline HBV DNA levels are associated with poor prognosis in the patients with early‑stage HCC, 
and the antiviral treatment could generate survival benefits for the patients. Therefore, antiviral treatment should be 
given for these patients. However, the effect of antiviral treatment on the patients with low viral load remains unclear, 
and further investigation is warranted.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in men and the seventh most common can-
cer in women, and it is the third most common cause of 
cancer-related death worldwide [1]. The 2010 incidence 
and mortality of liver cancer in China were among high 
levels worldwide [2]. Most HCCs develop within an 
established background of chronic liver disease, and the 
most common risk factor for HCC is hepatitis B virus 
(HBV) infection [3]. High levels of serum HBV DNA are 
associated with an increased risk of developing HCC 
[4], and nomograms based on clinical characteristics, 
including serum hepatitis B e antigen (HBeAg) status 
and HBV DNA level, can predict the risk of developing 
HCC [5]. Additionally, in HBV-related HCC, high levels 
of serum HBV DNA appear to be associated with poor 
prognosis [6–8]. Therefore, careful management of HBV 
infection is needed in the management of HBV-related 
HCC [9].
Hepatic resection has been the standard curative 
treatment for HCC. However, a high rate of tumor 
recurrence has been reported after surgery [10]. So 
far, no effective adjuvant treatment option has been 
proven to reduce the risk of recurrence [11]. Recently, 
some studies demonstrated that antiviral therapy with 
nucleotide/nucleoside analogs (NAs) was associated 
with prolonged disease-free survival (DFS) and overall 
survival (OS) after hepatectomy of HBV-related HCC, 
suggesting that antiviral treatment may offer clinical 
benefits in HCC patients with HBV infection [12–15]. 
However, most of these studies did not stratify the 
patients into specific subgroups based on tumor stages 
or HBV DNA levels, and the results of these studies 
were contradictory. Early-stage tumors tend to be asso-
ciated with a better prognosis than intermediate-stage 
tumors, and antiviral treatment may confer a significant 
survival benefit compared with non-antiviral treatment 
[16, 17]. Another issue that should be considered is the 
HBV DNA load. Whether it is necessary to give antiviral 
treatment to HCC patients with low or even undetect-
able HBV DNA levels remains controversial [18, 19]. 
So far, no consensus on this issue exists, and the indi-
cations for antiviral treatment in patients with HBV-
related HCC remain uncertain.
In this retrospective study, we used strict classifica-
tion of patients into subgroups, comparison of DFS and 
OS, and multivariate analysis to (1) evaluate the effect of 
HBV DNA on the prognosis of patients with early-stage 
[stages I and II; Union for International Cancer Control 
(UICC), 7th edition] HCC who underwent curative ther-
apy and (2) analyze the effect of antiviral treatment on 




This retrospective cohort study in a tertiary academic 
hospital was approved by the Institutional Review Board 
of Sun Yat-sen University Cancer Center in Guangdong, 
China. We included patients who were initially diagnosed 
with hepatitis B surface antigen (HBsAg)-positive HCC 
and underwent curative resection between January 2005 
and December 2008 at the Hepatobiliary Department of 
Sun Yat-sen University Cancer Center. Prior to obtain-
ing tissues, written informed consent was obtained from 
each patient.
Preoperative evaluation
As described previously [20], baseline examinations 
(within 10  days before surgery), including serum HBV 
DNA quantification, detection of HBsAg, and liver func-
tion tests, were routinely performed. Serum HBV viral 
loads were measured by using a quantitative fluorescence 
polymerase chain reaction detection kit (DaAn Gene 
Corporation, Guangzhou, China) with a lower detec-
tion limit of 200  IU/mL. Dynamic contrast-enhanced 
computed tomography (CT) and/or magnetic resonance 
imaging (MRI) were used to assess the intrahepatic 
tumor. The preoperative diagnosis of HCC was based on 
the criteria established by the European Association for 
the study of the liver [21].
Inclusion criteria
To be included in our study, patients had to meet the 
following criteria: (1) ≥18  years old, (2) hepatic resec-
tion for initial HCC treatment, (3) UICC TNM stage 
T1N0M0 or T2N0M0, (4) curative treatment (pathologic 
confirmation of negative resection margin) and no local 
recurrence within 3 months after surgery, (5) HBsAg pos-
itivity, (6) no anti-HBV treatment before surgery, (7) ade-
quate baseline liver function (Child-Pugh grade A) and 
adequate renal function (serum creatinine <124 µmol/L), 
and (8) no tumor rupture before or during surgery.
Exclusion criteria
Patients who met any of the following criteria were 
excluded: (1) HBsAg negativity, (2) evidence of co-infec-
tion with other hepatotropic viruses or human immu-
nodeficiency virus, (3) any prior treatment for HCC, (4) 
Child-Pugh grade B or C, (5) presence of other malig-
nancy or concurrent non-malignant severe illness, (6) 
tumor stage beyond T2N0M0, (7) recurrence or metas-
tasis within 3 months after surgery, (8) interferon admin-
istration after surgery, (9) initiation of NA administration 
after tumor recurrence, and (10) severe complications or 
adverse events (including postoperative mortality) within 
3 months after surgery.
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Tumor characteristics
The diagnosis of HCC was pathologically confirmed 
after surgery, and the histological differentiation of the 
tumors were graded from I to IV based on the Edmond-
son–Steiner classification [22]. Tumor number, maximal 
tumor size, tumor differentiation, tumor capsulation, the 
presence of microvascular invasion, and surgical margin 
were evaluated. Tumor characteristics and UICC TNM 
stage were comprehensively evaluated.
Definition of curative resection
None of the cases had major vascular invasion. Cura-
tive resection was defined as complete removal of all 
macroscopically evident tumors [15, 23]. The absence of 
tumor cells along the parenchymal transection line was 
confirmed histologically. The CT or MRI examination 
performed 3 months after surgery showed no remaining 
tumor.
Follow‑up protocol
After discharge, each patient received regular examina-
tions and follow-up at 3-month intervals until 3  years 
after resection, and at 4- to 6-month intervals there-
after. Follow-up ended on December 31, 2014. Serum 
liver function tests, alpha-fetoprotein (AFP) tests, chest 
X-ray radiography, abdominal ultrasonography, and CT/
MRI scans were the routine examinations to determine 
possible recurrence or metastasis. Hepatic angiography, 
ultrasonic contrast, positron emission tomography/com-
puted  tomography, and ultrasound-guided biopsy were 
performed when necessary.
Statistical analysis
Demographic data [mean, standard deviation, median 
(P25, P75), and percentage] were calculated. Analyses 
were conducted using the independent Student’s t test 
(Mann–Whitney test for non-normal distributions), 
analysis of variance (Kruskal–Wallis test for non-normal 
distributions), and the Chi square test, as appropriate. 
The Kaplan–Meier method and the log-rank test were 
used for survival analysis. DFS was the time calculated 
from the date of curative surgery to HCC recurrence, 
death, or the last follow-up; OS was the time calculated 
from the date of surgery to death or the last follow-up. 
The Cox proportional hazards model was used in the uni-
variate survival analysis to determine the association of 
individual clinical variables with OS or DFS. All variables 
with P  <  0.1 were subsequently subjected to the multi-
variate Cox regression model to determine the hazard 
ratios (HRs) and the independence of effects. P  <  0.05 
were considered statistically significant. All statistical 
tests were two-sided. Data were analyzed using the SAS 
9.1 software (SAS Institute, Cary, NC, USA).
Results
General description
During the study period, 729 HCC patients underwent 
hepatic resection as their initial treatment at Sun Yat-sen 
University Cancer Center. According to our inclusion and 
exclusion criteria, 284 patients were excluded, and the 
remaining 445 patients were enrolled. The patient flow 
diagram is shown in Fig. 1.
In total, 192 patients received oral administration 
of NAs after surgery, with a median antiviral time of 
79 months (P25, 47 months; P75, 87 months). Of these, 
93, 84, 13, and 2 patients took entecavir, lamivudine, 
adefovir dipivoxil, and telbivudine as their initial antivi-
ral agent, respectively. During the follow-up, 13 patients 
received sequential treatments due to partial HBV 
response or HBV resistance. The common treatment reg-
imens involved lamivudine followed by entecavir-switch 
(four patients) and adefovir add-on (six patients). Other 
regimens included adefovir followed by entecavir-switch 
(two patients) and entecavir add-on (one patient).
Fig. 1 Selection of patients with early stage HBV‑related HCC under‑
going curative resection. HCC hepatocellular carcinoma, SYSUCC Sun 
Yat‑sen University Cancer Center, HBsAg hepatitis B surface antigen, 
HCV-Ab hepatitis C virus antibody, TNM tumor‑nodes‑metastasis, OS 
overall survival time, DFS disease‑free survival time, HBV hepatitis B 
virus
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Based on the stratification of baseline HBV DNA and 
antiviral therapy, the patients were classified into four 
subgroups: (1) subgroup 1, antiviral therapy with baseline 
HBV DNA ≥2000 IU/mL (n = 141); (2) subgroup 2, anti-
viral therapy with baseline HBV DNA <2000  IU/mL or 
undetectable (n = 51); (3) subgroup 3, no antiviral ther-
apy with baseline HBV DNA ≥2000 IU/mL (n = 99); and 
(4) subgroup 4, no antiviral therapy with baseline HBV 
DNA <2000 IU/mL or undetectable (n = 154).
Table  1 summarizes the characteristics of the anti-
viral group and non-antiviral group. Most variables 
were similar between these two groups. However, there 
were significant differences in HBeAg, HBV DNA, ala-
nine aminotransferase (ALT), and serum total bilirubin 
levels, which may be explained by the fact that, in this 
Table 1 Comparison of  clinicopathologic characteristics 
between antiviral and non-antiviral groups






 Mean ± SDb 47.9 ± 10.3 48.8 ± 11.8
 Median and rangeb 47 (24–76) 49 (23–79)
 <50 111 128
 ≥50 81 125
Gender 0.278
 Male 172 218
 Female 20 35
HBeAg 0.003
 Positive 48 35
 Negative 144 218
HBV DNA (IU/mL) <0.001
 <2000 51 154
 ≥2000 141 99
Tumor size (cm) 0.012a
 Mean ± SDb 4.7 ± 3.1 5.4 ± 3.2
 Rangeb 1.0–25.0 1.0–18.0
 <5 122 121
 ≥5 70 132
Tumor number 0.990
 Single 176 232
 Multiple 16 21
Pathologic grade 0.961
 I 12 21
 II 121 150
 III 58 80
 IV 1 2
Microvascular thrombus 0.054
 Yes 25 19
 No 167 234
Antiviral group resection plus postsurgical antiviral treatment group, Non-
antiviral group resection alone group, HBV hepatitis B virus, SD standard 
deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-
fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB 
serum albumin, TBIL serum total bilirubin
 a  t test used
b  Except for these values, other values are presented as the number of patients 
and were compared by the χ2 test
Table 1 continued






 Complete 87 112
 Incomplete 60 66
 Without 45 75
TNM stage 0.083
 I 151 215
 II 41 38
AFP (ng/mL) 0.881
 ≤25 78 101
 >25 114 152
ALT (IU/L) 0.002a
 Mean ± SDb 49.8 ± 30.3 41.9 ± 24.6
 Rangeb 13.1–209.2 8.5–163.0
 ≤40 83 150
 >40 109 103
AST (IU/L) 0.115a
 Mean ± SDb 41.6 ± 25.2 38.2 ± 20.4
 Rangeb 8.0–263.0 15.0–168.0
 ≤45 138 189
 >45 54 64
ALB (g/L) 0.485a
 Mean ± SDb 43.1 ± 3.6 42.8 ± 4.0
 Rangeb 29.3–52.5 27.8–51.6
 <35 3 8
 ≥35 189 245
TBIL (μmol/L) 0.035a
 Mean ± SDb 15.9 ± 7.3 14.6 ± 5.6
 Rangeb 4.6–63.3 5.0–47.2
 ≤20.5 156 217
 >20.5 36 36
Prothrombin time (s) 0.215a
 Mean ± SDb 12.7 ± 1.5 12.5 ± 1.3
 Rangeb 9.6–19.1 9.4–17.4
 ≤13.5 139 207
 >13.5 53 46
Recurrence 0.489
 Yes 105 130
 No 87 123
Death 0.043
 Yes 51 90
 No 141 163
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retrospective study, patients with higher HBV replica-
tion or more severe liver damage tended to be treated 
with antiviral therapy. The median follow-up period was 
74 months. Of the 445 patients, 235 (52.8 %) experienced 
tumor recurrence, and 141 (31.7 %) died during the fol-
low-up period. The 1-, 3-, 5-, 7-, and 10-year OS rates 
in all study patients were 96.1 %, 82.6 %, 73.4 %, 65.6 %, 
and 62.8 %, respectively, whereas DFS rates were 79.8 %, 
59.8 %, 51.2 %, 43.3 %, and 42.2 %, respectively (Fig. 2).
OS and DFS analysis for all patients
OS
Patients in the antiviral group had higher OS rates than 
patients in the non-antiviral group (P =  0.023; Fig.  3a). 
The 1-, 3-, 5-, 7-, and 10-year OS rates in the antiviral 
group were 96.4  %, 86.9  %, 77.6  %, 71.3  %, and 71.3  %, 
respectively, whereas the corresponding rates in the non-
antiviral group were 96.0 %, 78.8 %, 69.5 %, 61.4 %, and 
56.9  %, respectively. Univariate analysis revealed that 
HBeAg, HBV DNA level, tumor size, tumor number, 
pathologic differentiation grade, microvascular throm-
bus, aspartate aminotransferase (AST) level, albumin 
(ALB) level, antiviral treatment, and recurrence were 
associated with OS (Table  2). On multivariate analysis, 
high baseline HBV DNA, multiple tumors, high patho-
logic grade, presence of microvascular thrombus, low 
ALB level, no antiviral treatment, and recurrence were 
independent risk factors that associated with short OS 
(Table 2).
DFS
The 1-, 3-, 5-, 7-, and 10-year DFS rates in the antiviral 
group were 82.8  %, 61.9  %, 51.5  %, 41.8  %, and 41.8  %, 
respectively, whereas the corresponding rates in the non-
antiviral group were 77.6 %, 57.7 %, 51.0 %, 43.8 %, and 
42.3 %, respectively. No significant difference in DFS rates 
were observed between these two groups (P  =  0.809; 
Fig.  3b). Univariate analysis showed that HBeAg, HBV 
DNA level, tumor size, tumor number, and AST level 
were associated with DFS (Table  2). On multivariate 
analysis, high baseline HBV DNA, tumor size larger than 
5 cm, and multiple tumors were independent risk factors 
that associated with short DFS.
Baseline HBV DNA levels as a risk factor for both OS and DFS
Kaplan–Meier analysis revealed that the OS rates in 
patients with baseline HBV DNA <2000 IU/mL or unde-
tectable were significantly higher than those in patients 
with HBV DNA levels ≥2000 IU/ml (P = 0.008; Fig. 3c). 
A similar result was found in the analysis of DFS rates 
(P = 0.002; Fig. 3d). Univariate and multivariate analyses 
Fig. 2 Kaplan–Meier survival curves for overall survival (OS) and disease‑free survival (DFS) in patients who underwent curative resection (n = 445). 
CI confidence interval
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demonstrated that high baseline HBV DNA was a risk 
factor for short DFS and OS (Table 2).
Analysis based on the stratification of baseline HBV DNA 
and antiviral therapy
We stratified all patients by the levels of baseline HBV 
DNA between the antiviral and non-antiviral groups 
and evaluated the association of antiviral treatment with 
long-term prognosis in each stratum. Table  3 summa-
rizes the characteristics of these four subgroups.
The association between baseline HBV DNA and the 
prognosis of the non‑antiviral group (n = 253)
For the 253 patients in the non-antiviral group (sub-
groups 3 and 4), Kaplan–Meier analysis showed that 
higher baseline HBV DNA levels were associated 
with lower DFS and OS rates (Fig.  4a for OS analy-
sis, P  =  0.001; Fig.  4b for DFS analysis, P  <  0.001). 
Univariate and multivariate Cox models showed that 
high baseline HBV DNA along with some tumor char-
acteristics (multiple tumors, tumor size larger than 
5  cm, and presence of microvascular thrombus) were 
risk factors for short DFS and OS in the non-antiviral 
group (Table 4).
The effect of antiviral treatment on the prognosis of patients 
with high baseline HBV DNA (≥2000 IU/mL)
In the antiviral group with high baseline HBV DNA, 
the OS rate was significantly higher than that of the 
non-antiviral group (Fig.  4a, subgroup 1 vs. subgroup 
3, P =  0.001). Both univariate and multivariate analy-
ses identified antiviral treatment as a risk factor linked 
to OS (Table  5). As to the analysis of DFS, antiviral 
treatment conferred a significantly higher DFS rate 
(Fig. 4b, subgroup 1 vs. subgroup 3, P = 0.041). On uni-
variate analysis, tumor size, tumor number, AST level, 
Fig. 3 Kaplan–Meier survival curves of patients with various baseline HBV levels and use of nucleotide/nucleoside analogs (NAs). a OS rates 
between the antiviral and non‑antiviral groups. b DFS rates between the antiviral and non‑antiviral groups. c OS rates between patients with 
baseline serum HBV DNA levels of ≥2000 and <2000 IU/mL or undetectable. d DFS rates between patients with baseline serum HBV DNA levels of 
≥2000 and <2000 IU/mL or undetectable
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and antiviral treatment were significantly associated 
with DFS. On multivariate analysis, tumor size, tumor 
number, and AST level were independent risk factors 
linked to DFS, whereas antiviral treatment was not 
an independent protective factor of DFS in the model 
(Table 5).
The effect of antiviral treatment on the prognosis of patients 
with low (<2000 IU/mL) or undetectable baseline HBV DNA
Kaplan–Meier analysis showed no significant difference 
in OS rates between antiviral and non-antiviral treatment 
groups in patients with low or even undetectable baseline 
HBV DNA (Fig. 4a, subgroup 2 vs. subgroup 4, P = 0.202). 
Univariate analysis identified the following factors as sig-
nificantly associated with OS: tumor size, tumor number, 
and recurrence. On multivariate analysis, only recurrence 
was an independent risk factor linked to OS (Table  6). 
As to the analysis of DFS, no significant difference was 
observed in DFS rates between the antiviral and non-
antiviral groups in patients with low or even undetect-
able baseline HBV DNA (Fig. 4b, subgroup 2 vs. subgroup 
4, P  =  0.777). Both univariate and multivariate analyses 
showed that tumor number and tumor size were prog-
nostic factors related to DFS (Table 6). Antiviral treatment 
was not a risk factor related to OS or DFS in the analysis.
Patients with high HBV DNA load and no antiviral treatment 
had the worst prognosis
Kaplan–Meier analysis showed that subgroup 3 had a sig-
nificantly lower OS rate compared with the other three 
subgroups (subgroup 3 vs. subgroup 1, P =  0.001; sub-
group 3 vs. subgroup 2, P =  0.000; subgroup 3 vs. sub-
group 4, P =  0.001). Among subgroups 1, 2, and 4, the 
differences were not significant (Fig. 4a).
As for DFS, similarly, subgroup 3 had a significantly 
lower DFS rate compared with the other three sub-
groups (subgroup 3 vs. subgroup 1, P = 0.041; subgroup 
3 vs. subgroup 2, P = 0.009; subgroup 3 vs. subgroup 4, 
P =  0.000). Subgroup 4 appeared to have a higher DFS 
rate than subgroup 1, but the difference was not sig-
nificant (P  =  0.082). As to the comparisons between 
subgroups 2 and 4 and between subgroups 1 and 2, the 
differences were not significant (Fig. 4b).
Table 2 Relationship between clinical characteristics and overall survival (OS)/disease-free survival (DFS), as determined 
by univariate and multivariate Cox regression analysis
CI confidence interval, HR hazard ratio, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral group resection alone group, HBV hepatitis 
B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate 




Multivariate analysis Univariate 
analysis
Multivariate analysis
HR P value HR (95 % CI) P value HR P value HR (95 % CI) P value
Age (≥50 vs. <50 years) 1.320 0.101 1.116 0.401
Gender (female vs. male) 0.951 0.845 0.921 0.684
HBeAg (positive vs. negative) 1.582 0.020 Not significant 1.403 0.034 Not significant
HBV DNA (≥2000 vs. <2000 IU/mL) 1.580 0.009 1.615 (1.126–2.317) 0.009 1.511 0.002 1.496 (1.150–1.944) 0.003
Tumor size (≥5 vs. <5 cm) 1.745 0.001 Not significant 1.687 <0.001 1.868 (1.432–2.435) <0.001
Tumor number (multiple vs. single) 2.347 <0.001 1.930 (1.196–3.113) 0.007 1.961 0.001 2.437 (1.607–3.696) <0.001
Pathologic grade (IV/III/II/I) 1.413 0.014 1.412 (1.064–1.875) 0.017 1.172 0.145
Microvascular thrombus (yes vs. no) 2.076 0.002 2.339 (1.456–3.759) <0.001 1.315 0.188
Tumor capsule (without/incomplete/complete) 1.123 0.244 0.950 0.520
AFP (>25 vs. ≤25 ng/mL) 1.181 0.335 1.079 0.568
ALT (>40 vs. ≤40 IU/L) 1.249 0.188 1.212 0.141
AST (>45 vs. ≤45 IU/L) 1.510 0.023 Not significant 1.597 0.001 Not significant
ALB (≥35 vs. <35 g/L) 0.358 0.008 0.383 (0.176–0.833) 0.015 0.661 0.250
TBIL (>20.5 vs. ≤20.5 μmol/L) 1.407 0.097 Not significant 1.227 0.222
Prothrombin time (>13.5 vs. ≤13.5 s) 1.051 0.799 1.011 0.942
Antiviral treatment (yes vs. no) 0.672 0.024 0.516 (0.359–0.743) <0.001 0.969 0.809
Recurrence (yes vs. no) 7.785 <0.001 7.208 (4.418–11.760) <0.001
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P1 P2 P3 P4
Age (years) 0.290a 0.042a 0.108a 0.526a
 Mean ± SDb 48.4 ± 10.6 46.6 ± 9.6 50.7 ± 11.9 47.6 ± 11.7
 <50 78 33 41 87
 ≥50 63 18 58 67
Gender 0.216 0.527 0.988 0.092
 Males 124 48 87 131
 Females 17 3 12 23
HBeAg 0.011 <0.001 0.441 0.360
 Positive 42 6 25 10
 Negative 99 45 74 144
Tumor size (cm) 0.233a 0.922a 0.158a 0.020a
 Mean ± SDb 4.8 ± 3.1 4.2 ± 2.8 5.4 ± 3.1 5.5 ± 3.3
 <5 86 36 45 76
 ≥5 55 15 54 78
Tumor number 0.460 0.194 0.278 0.360
 Single 131 45 88 144
 Multiple 10 6 11 10
Pathologic grade 0.561 0.375 0.498 0.444
 I 10 2 12 9
 II 85 36 56 94
 III 45 13 30 50
 IV 1 0 1 1
Microvascular thrombus 0.756 0.210 0.430 0.273
 Yes 19 6 10 9
 No 122 45 89 145
Tumor capsule (cases) 0.083 0.729 0.056 0.648
 Complete 64 23 43 69
 Incomplete 49 11 24 42
 Without 28 17 32 43
Liver cirrhosis 0.017 0.738 0.852 0.012
 Yes 101 45 72 109
 No 40 6 27 45
AFP (ng/mL) 0.216 0.514 0.897 0.523
 ≤25 61 17 42 59
 >25 80 34 57 95
ALT (IU/L) 0.052a <0.001a 0.485a 0.220a
 Mean ± SDb 52.4 ± 29.3 42.8 ± 32.1 49.8 ± 26.0 36.8 ± 22.3
 ≤40 53 30 46 104
 >40 88 21 53 50
AST (IU/L) 0.009a 0.008a 0.508a 0.596a
 Mean ± SDb 44.4 ± 27.1 33.7 ± 16.8 42.4 ± 17.6 35.5 ± 21.6
 ≤45 96 42 62 127
 >45 45 9 37 27
ALB (g/L) 0.028a 0.092a 0.372a 0.168a
 Mean ± SDb 42.8 ± 3.5 44.1 ± 3.7 42.3 ± 4.0 43.2 ± 3.9
 <35 2 1 95 150
 ≥35 139 50 4 4










P1 P2 P3 P4
TBIL (μmol/L) 0.931a 0.878a 0.114a 0.193a
 Mean ± SDb 16.0 ± 7.8 15.9 ± 5.8 14.5 ± 5.4 14.6 ± 5.8
 ≤20.5 116 40 84 133
 >20.5 25 11 15 21
Prothrombin time (s) 0.929a 0.182a 0.824a 0.345a
 Mean ± SDb 12.7 ± 1.5 12.7 ± 1.6 12.6 ± 1.3 12.4 ± 1.2
 ≤13.5 101 38 76 131
 >13.5 40 13 23 23
Recurrence 0.535 0.001 0.180 0.312
 Yes 79 26 64 66
 No 62 25 35 88
Death 0.189 0.001 0.731 0.276
 Yes 41 10 48 42
 No 100 41 51 112
Definition of the four subgroups: (1) subgroup 1, antiviral therapy and baseline HBV DNA ≥ 2000 IU/mL (n = 141); (2) subgroup 2, antiviral therapy and baseline HBV 
DNA <2000 IU/mL or undetectable (n = 51); (3) subgroup 3, non-antiviral therapy and baseline HBV DNA ≥2000 IU/mL (n = 99); and (4) subgroup 4, non-antiviral 
therapy and baseline HBV DNA <2000 IU/mL or undetectable (n = 154)
P1 P value calculated by comparing subgroup 1 and subgroup 2, P2 P value calculated by comparing subgroup 3 and subgroup 4, P3 P value calculated by comparing 
subgroup 1 and subgroup 3, P4 P value calculated by comparing subgroup 2 and subgroup 4, Antiviral group resection plus postsurgical antiviral treatment group, 
Non-antiviral group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-
fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB serum albumin, TBIL serum total bilirubin
a t test used
b  Except for these values, other values are presented as the number of patients and were compared by the χ2 test
Fig. 4 Kaplan–Meier survival curves of patients in antiviral and non‑antiviral subgroups after stratification with baseline HBV DNA loads. a OS rates 
among the four subgroups of patients (log‑rank test: subgroup 3 vs. subgroup 1, P = 0.001; subgroup 3 vs. subgroup 2, P < 0.001; subgroup 3 vs. 
subgroup 4, P = 0.001; subgroup 1 vs. subgroup 2, P = 0.142; subgroup 1 vs. subgroup 4, P = 0.837; subgroup 2 vs. subgroup 4, P = 0.202). b DFS 
rates among the four subgroups of patients (subgroup 3 vs. subgroup 1, P = 0.041; subgroup 3 vs. subgroup 2, P = 0.009; subgroup 3 vs. subgroup 
4, P = 0.000; subgroup 1 vs. subgroup 2, P = 0.292; subgroup 1 vs. subgroup 4, P = 0.082; subgroup 2 vs. subgroup 4, P = 0.777). [Note: (1) Sub‑
group 1, antiviral treatment with baseline hepatitis B virus (HBV) DNA ≥2000 IU/mL (n = 141); (2) Subgroup 2, antiviral treatment with baseline HBV 
DNA <2000 IU/mL or undetectable (n = 51); (3) Subgroup 3, no antiviral treatment with baseline HBV DNA ≥2000 IU/mL (n = 99); and (4) Subgroup 
4, no antiviral treatment with baseline HBV DNA <2000 IU/mL or undetectable (n = 154).]
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Table 4 Relationship between  clinical characteristics and  OS/DFS in  patients without  antiviral treatment (n =  253), 
as determined by univariate and multivariate Cox regression analysis
OS overall survival, DFS disease-free survival, CI confidence interval, HR hazard ratio, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral 
group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT 




Multivariate analysis Univariate 
analysis
Multivariate analysis
HR P value HR (95 % CI) P value HR P value HR (95 % CI) P value
Age (≥50 vs. <50 years) 1.341 0.169 0.933 0.693
Gender (female vs. male) 0.891 0.710 0.827 0.465
HBeAg (positive vs. negative) 1.681 0.054 Not significant 1.716 0.019 Not significant
HBV DNA (≥2000 vs. <2000 IU/mL) 2.056 0.001 1.589 (1.042–2.422) 0.031 1.840 0.001 1.705 (1.204–2.415) 0.003
Tumor size (≥5 vs. <5 cm) 1.820 0.006 1.689 (1.087–2.624) 0.020 1.655 0.005 1.713 (1.195–2.455) 0.003
Tumor number (multiple vs. single) 2.393 0.004 2.259 (1.223–4.172) 0.009 2.227 0.004 2.571 (1.470–4.499) 0.001
Pathologic grades (IV/III/II/I) 1.357 0.075 Not significant 1.288 0.074 Not significant
Microvascular thrombus (yes vs. no) 2.915 0.001 2.587 (1.345–4.978) 0.004 1.969 0.021 1.192 (1.066–3.429) 0.030
Tumor capsule (without/incomplete/complete) 1.028 0.825 0.880 0.226
AFP (>25 vs. ≤25 ng/mL) 1.252 0.302 1.064 0.728
ALT (>40 vs. ≤40 IU/L) 1.539 0.041 Not significant 1.375 0.072 Not significant
AST (>45 vs. ≤45 IU/L) 1.803 0.009 Not significant 1.687 0.006 Not significant
ALB (≥35 vs. <35 g/L) 0.423 0.061 Not significant 0.643 0.291
TBIL (>20.5 vs. ≤20.5 μmol/L) 0.919 0.780 1.126 0.618
Prothrombin time (>13.5 vs. ≤13.5 s) 1.146 0.593 1.015 0.945
Recurrence (yes vs. no) 6.671 <0.001 5.442 (3.091–9.582) <0.001
Table 5 Relationship between  clinical characteristics and  OS/DFS in  patients with  high HBV DNA level (≥2000  IU/mL), 
as determined by univariate and multivariate Cox regression analysis
OS overall survival, DFS disease-free survival, CI confidence interval, HR hazard ratio, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral 
group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT 




Multivariate analysis Univariate 
analysis
Multivariate analysis
HR P value HR (95 % CI) P value HR P value HR (95 % CI) P value
Age (≥50 vs. <50 years) 1.329 0.186 1.384 0.055 Not significant
Gender (female vs. male) 1.087 0.795 0.914 0.737
HBeAg (positive vs. negative) 1.407 0.132 1.216 0.290
Tumor size (≥5 vs. <5 cm) 1.618 0.024 Not significant 1.618 0.004 1.650 (1.162–2.342) 0.005
Tumor number (multiple vs. single) 2.175 0.010 Not significant 1.796 0.028 2.104 (1.218–3.635) 0.008
Pathologic grades (IV/III/II/I) 1.365 0.070 1.613 (1.129–2.305) 0.009 1.100 0.476
Microvascular thrombus (yes vs. no) 2.038 0.010 2.688 (1.534–4.710) 0.001 1.128 0.640
Tumor capsule (without/incomplete/complete) 1.201 0.148 1.030 0.771
AFP (>25 vs. ≤25 ng/mL) 1.291 0.240 1.030 0.863
ALT (>40 vs. ≤40 IU/L) 1.064 0.774 1.088 0.621
AST (>45 vs. ≤45 IU/L) 1.657 0.018 Not significant 1.688 0.002 1.486 (1.057–2.090) 0.023
ALB (≥35 vs. <35 g/L) 0.294 0.008 Not significant 0.633 0.316
TBIL (>20.5 vs. ≤20.5 μmol/L) 1.566 0.077 Not significant 1.098 0.672
Prothrombin time (>13.5 vs. ≤13.5 s) 0.867 0.557 0.814 0.283
Antiviral treatment (yes vs. no) 0.499 0.001 0.475 (0.309–0.729) 0.001 0.710 0.042 Not significant 0.120
Recurrence (yes vs. no) 9.514 <0.001 9.954 (4.781–20.725) <0.001
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Discussion
In the present study, we found that baseline HBV DNA 
level was a significant prognostic factor that influenced 
both OS and DFS of early-stage HCC patients under-
going curative resection, which was consistent with the 
findings of most previous studies [24–27]. The precise 
mechanism for recurrent carcinogenesis in patients with 
high HBV DNA levels remains unclear. It is possible that 
active viral replication may contribute to hepatocarcino-
genesis by direct and indirect pathways [28]. Clearly, 
recurrence tends to shorten OS of cancer patients. 
One study showed that sustained low HBV load below 
2000 IU/mL was a strong protective factor for long-term 
DFS and OS after curative resection in HBV-related HCC 
[23]. In addition, the effect of NAs differs in patients with 
different tumor stages [16, 29]. Therefore, HBV DNA 
level, tumor stage, and liver function should be consid-
ered before administration of NAs [18].
In the present study, no significant differences were 
observed in DFS rates between the antiviral and non-
antiviral groups, whereas the OS rates were higher in the 
antiviral group than in the non-antiviral group. Treat-
ment was an independent prognostic factor related to 
OS, which is consistent with the results of a prospec-
tive-retrospective study carried out in Hong Kong [30]. 
However, other studies reported that antiviral therapy 
reduced the risk of recurrence of HCC after curative 
therapy [14, 15]. The discrepancy in the results regarding 
tumor recurrence could be due to different study popula-
tions (including tumor stage) and study designs. As to the 
effect of antiviral therapy on OS, there are several pos-
sible explanations. First, antiviral treatment could reduce 
the risk of HBV reactivation, and subsequent liver dys-
function after surgery, which would reduce perioperative 
liver-related mortality [20, 31]. Second, better liver func-
tion preservation at the time of recurrence could trans-
late into a high proportion of patients receiving more 
aggressive curative or palliative treatment at the time of 
recurrence to extend OS [30, 32]. Third, although not 
well defined, antiviral therapy can decrease the hepatitis 
activity caused by HBV, leading to a reduced risk of late-
phase recurrence of HCC, which can therefore increase 
the OS rate [33].
In the stratification analyses, antiviral treatment was 
associated with better prognosis (both OS rate and DFS 
rate) in patients with high baseline HBV DNA levels. 
However, in patients with low or undetectable baseline 
HBV DNA levels, no significant difference was found 
in either DFS rate or OS rate between the antiviral and 
non-antiviral groups. In this population, univariate and 
Table 6 Relationship between clinical characteristics and OS/DFS in patients with undetectable or low baseline HBV DNA 
levels (<2000 IU/mL), as determined by univariate and multivariate Cox regression analysis
OS overall survival, DFS disease-free survival, CI confidence interval, HR hazard ratio, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral 
group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT 




Multivariate analysis Univariate 
analysis
Multivariate analysis
HR P value HR (95 % CI) P value HR P value HR (95 % CI) P value
Age (≥50 vs. <50 years) 1.173 0.566 0.750 0.183
Gender (female vs. male) 0.819 0.645 0.963 0.902
HBeAg (positive vs. negative) 1.321 0.554 1.407 0.330
Tumor size (≥5 or <5 cm) 2.013 0.013 Not significant 1.772 0.006 1.997 (1.295–3.044) 0.002
Tumor number (multiple vs. single) 2.612 0.013 Not significant 2.194 0.015 2.761 (1.440–5.296) 0.002
Pathologic grades (IV/III/II/I) 1.535 0.073 Not significant 1.346 0.100 Not significant
Microvascular thrombus (yes vs. no) 1.902 0.140 1.561 0.205
Tumor capsule (without/incomplete/complete) 1.046 0.784 0.873 0.284
AFP (>25 vs. ≤25 ng/mL) 1.084 0.777 1.230 0.345
ALT (>40 vs. ≤40 IU/L) 1.219 0.487 1.115 0.618
AST (>45 vs. ≤45 IU/L) 0.820 0.626 1.107 0.712
ALB (≥35 vs. <35 g/L) 0.490 0.324 0.712 0.562
TBIL (>20.5 vs. ≤20.5 μmol/L) 1.167 0.661 1.439 0.158
Prothrombin time (>13.5 vs. ≤13.5 s) 1.296 0.432 1.272 0.342
Antiviral treatment (yes vs. no) 0.641 0.206 1.068 0.777
Recurrence (yes vs. no) 5.859 <0.001 5.859 (3.007–11.416) <0.001
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multivariate analysis did not identify antiviral treatment 
as a risk factor for DFS or OS. A previous study demon-
strated that patients with persistently low HBV DNA lev-
els had better survival results compared with those with 
high or fluctuating HBV DNA levels [23]. Although the 
stratification in our study was based on the evaluation of 
baseline HBV DNA at resection, most (135/154, 87.6 %) 
of the HBV DNA levels in subgroup 4 remained stable 
during the follow-up period (data not shown). In 33.1 % 
(51/154) of the patients, serum HBV DNA was even 
undetectable. The results indicated that HCC patients 
with low or undetectable HBV DNA load may not signifi-
cantly benefit from antiviral therapy as patients with high 
HBV DNA load did.
However, some weaknesses could be noted in our 
study. First, the proportion of para-tumorous liver cir-
rhosis was higher in subgroup 2 (Table 3), which may be 
explained by the fact that patients with cirrhosis were 
more likely to be treated with NAs. Second, the mean 
tumor size in subgroup 2 was smaller than that in sub-
group 4, which might have positively affected the out-
come of the antiviral group. Third, administration of 
NAs was not randomized, which may have caused selec-
tion bias. In addition, for the OS curves, a small gap was 
observed between these two subgroups (subgroups 2 and 
4), although no significant difference existed. Therefore, 
the results should be interpreted very carefully.
So far, no consensus exists on the indications of anti-
viral therapy for HCC patients with low HBV DNA load. 
Many guidelines have recommended NAs for patients 
with chronic HBV infection, evidence of active viral rep-
lication (≥2000 IU/mL), and elevated levels of ALT [18]. 
It remains controversial whether HCC patients with 
low HBV replication should be given antiviral therapy. 
In a study aimed to analyze the different prognosis after 
hepatectomy of HBV-related HCC with or without cir-
rhosis, the results revealed that antiviral treatment was 
an independent predictor for prolonged OS in HCC 
patients with cirrhosis [34]. However, in patients without 
cirrhosis, antiviral therapy did not significantly associ-
ated with either prolonged OS or prolonged DFS after 
radical resection, which indicated that HCC patients 
with cirrhosis benefit more from antiviral therapy than 
do those without cirrhosis. In a two-stage longitudinal 
clinical study, the investigators found that antiviral ther-
apy reduced HCC recurrence in patients with a low HBV 
load [13]. However, that study included patients with 
early Barcelona clinical liver cancer (BCLC) stage (0 to A) 
or intermediate stage (B), and the percentage of BCLC B 
stage in the non-antiviral group was nearly twice that of 
the antiviral group. Furthermore, several imbalances were 
observed between the antiviral and non-antiviral groups, 
including tumor encapsulation, tumor differentiation, 
and AFP [13]. Thus, the findings are not conclusive. Most 
recently, several studies showed that high levels of HBsAg 
were associated with short survival and early recurrence 
after surgery for HCC patients with low HBV viral loads 
[35–37], which may provide a clue for selecting suitable 
candidates for antiviral therapy from HCC patients with 
low viral load. However, further investigation is needed 
to determine the magnitude of benefit and to clarify 
whether NAs should be administered to all or only a sub-
set of patients (such as patients with cirrhosis or high lev-
els of HBsAg) after curative treatment for HBV-related 
HCC [33].
Our study also showed that DFS rate tended to be 
higher in the non-antiviral subgroup with low or unde-
tectable HBV DNA level than in the antiviral subgroup 
with high HBV DNA levels, although the OS rate was 
similar. Cho et al. [38] recently found that patients with 
active chronic hepatitis B (CHB) who were receiving 
long-term NA treatment had a higher incidence of HCC 
compared with patients with inactive CHB. One possi-
ble explanation is that the inactive CHB group may have 
had more intact immune response to HBV and, therefore, 
the HBV infection may have entered the inactive stage 
early in the patient’s life. However, in patients with high 
viral replication and active hepatitis, HBV DNA integra-
tion into hepatocytes that resulted in genomic altera-
tions and/or chromosomal instability may have already 
occurred before initiation of NA treatment. This may 
explain why, in our study, patients in subgroup 4 had a 
higher DFS rate than patients in subgroup 1 who were 
treated with NAs after surgery. However, a more detailed 
investigation is needed to confirm these results.
In the present retrospective study, we included only the 
patients with TNM stage I and II disease who had nor-
mal liver function before surgery (Child-Pugh grade A); 
we excluded those who experienced severe complications 
shortly after surgery. We evaluated only patients who were 
likely to receive curative treatment and tolerate it well. 
Therefore, the conclusions may not be generalizable to all 
HCC patients undergoing surgery. During the treatment 
period between January 2005 and December 2008, whether 
it was beneficial to give antiviral therapy to HBV-related 
HCC patients who underwent resection was controver-
sial at our institution. At that time, the major liver society 
guidelines for CHB only recommended that patients who 
had persistently elevated ALT levels more than two times 
the upper limit of normal should be considered for antivi-
ral treatment. Decisions on antiviral treatment were made 
on a case-by-case basis, which may have caused selection 
bias. Therefore, prospective large-scale trials, with hepati-
tis B and cirrhotic HCC patients at various stages, will be 
required in the future to clarify the effects of antiviral ther-
apy on survival and HCC recurrence [39].
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In conclusion, high baseline HBV DNA levels were 
associated with poor prognosis. For the patients with 
high HBV replication, antiviral treatment significantly 
improved patients’ long-term prognoses, including DFS 
and OS. However, for the patients with low or even unde-
tectable HBV DNA levels, whether the use of NAs is ben-
eficial remains unclear and requires further investigation.
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